Market Overview

UPDATE: Stifel Nicolaus Initiates Edwards Lifesciences at Buy on Growth Outlook

Related EW
Earnings Scheduled For October 26, 2015 (LH, BRCM, WCN, CR, JAKK, EW, SWFT, PMCS, CAKE, TMK, HIG, KN, AGII, WRB, ROP)
Edwards SAPIEN 3 Valve Demonstrates High Survival And Low Stroke Rate At 1 Year
Stocks Edge Higher In Pre-Thanksgiving Trade; Pfizer Leads Dow (Investor's Business Daily)

Stifel Nicolaus initiated coverage on Edwards Lifesciences (NYSE: EW) with a Buy rating and a $113 price target.

Stifel Nicolaus noted, "We are initiating coverage of Edwards Lifesciences Corp. (EW) shares with a Buy rating and a $113 12-month target price. Over time, we think that Edwards' current market leading TAVR share (approximately 64% WW), its healthy new product pipeline, and the move into new geographies (e.g.Japan) will substantially expand the company's profitability and drive sustained above-industry-average growth through mid-decade. As the Transcatheter Valve Replacement market evolves further in years ahead, we believe Edwards is poised to benefit, driving significant top-line growth and operating leverage."

Edwards Lifesciences closed at $85.74 on Monday.

Latest Ratings for EW

Nov 2015CitigroupInitiates Coverage onSell
Oct 2015Cowen & CompanyInitiates Coverage onOutperform
Aug 2015Credit SuisseAssumesOutperform

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (EW)

View Comments and Join the Discussion!

Get Benzinga's Newsletters